Procedural Advantages of a Novel Drug-Eluting Coronary Stent | NCT02881216 | Trialant

Procedural Advantages of a Novel Drug-Eluting Coronary Stent | NCT02881216 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Common DES	Other	Group of Patients with narrowed coronary artery disease, who were treated with an implantation of currently established drug-eluting stents (Xience Prime, Promus Element plus, Resolute Integrity).	Device: Currently common drug-eluting stent (DES)
Synergy Stent	Other	Group of Patients with narrowed coronary artery disease, who were treated with Synergy stent implantation	Device: Synergy Stent

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Synergy Stent	Device	Patients with narrowed coronary artery disease qualifying for PCI were treated with Synergy stent implantation.	Synergy Stent

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
In-hospital major cardiac adverse events	In-hospital major cardiac adverse events were collected up to one week after procedure throughout the in-patients stay	One week post-procedure

Condition Browse Module